Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 05 February 2016 | By Zachary Brennan
New information from France’s National Agency for Medicines and Health Products Agency (ANSM) was released this week on the Phase I clinical trial halted last month after the death of one healthy volunteer and the hospitalizations of five others.
ANSM said Thursday that it “is pursuing its investigations in an aim to identify the factors which led to the dramatic accident which occurred 3 weeks ago.” The agency said this work is meant to supplement other investigations from the judiciary authorities, the French General Inspectorate of Social Affairs (Inspection Générale des Affaires Sociales) and the Ministry of Health.
The trial was a first-in-human trial of Bial’s fatty acid amide hydrolase inhibitor and involved 128 healthy volunteers, 90 of whom received different doses of the drug.
Nineteen days after contract research organization (CRO) Biotrial dosed volunteers with 20 mg of the experimental drug, the CRO began treatment with a 50 mg dose on eight volunteers. On the fifth day of dosing, 10 January, one volunteer was hospitalized, though it wasn’t until 14 January that Biotrial informed ANSM of the serious adverse events.
On 11 January, a day after the hospitalization, seven other volunteers received another 50 mg dose. The hospitalized volunteer went into a coma later on the 11th and Biotrial and the sponsor Bial agreed to discontinue the trial. Five others were hospitalized between 13 and 15 January.
"All five volunteers hospitalized following the Bial study have returned home and two are being treated at centers close to their homes," Biotrial said on Twitter on Friday. The company also said "no critical observations were reported by the ANSM and we have responded to all comments."
The ongoing ANSM investigations include:
ANSM said the special committee, created 21 January, will explore all the pharmacological and toxicological hypotheses which could have led to the accident, including all of the pre-clinical and clinical data. On 15 February, the committee will meet and ANSM said the list of experts and the agenda will be published at least two days before the meeting. This committee's report will also be made public.
The UK’s Royal Statistical Society said in a statement that “there are clear statistical reservations about the study-design,” and it urged the French investigators to include independent statistician-members.
NOTE D’ETAPE : ENQUETE SUR DES INCIDENTS GRAVES SURVENUS DANS LE CADRE DE LA REALISATION D’UN ESSAI CLINIQUE (in French)
Tags: ANSM, Bial, Biotrial, France clinical trial